These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30093688)

  • 1. Does tau pathology activate jumping genes?
    Ridler C
    Nat Rev Neurol; 2018 Oct; 14(10):569. PubMed ID: 30093688
    [No Abstract]   [Full Text] [Related]  

  • 2. A new TAO kinase inhibitor reduces tau phosphorylation at sites associated with neurodegeneration in human tauopathies.
    Giacomini C; Koo CY; Yankova N; Tavares IA; Wray S; Noble W; Hanger DP; Morris JDH
    Acta Neuropathol Commun; 2018 May; 6(1):37. PubMed ID: 29730992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology.
    Dabir DV; Trojanowski JQ; Richter-Landsberg C; Lee VM; Forman MS
    Am J Pathol; 2004 Jan; 164(1):155-66. PubMed ID: 14695329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jumping genes: A quantum leap in tauopathy research.
    Stezin A; Pal PK
    Mov Disord; 2019 Jan; 34(1):46. PubMed ID: 30549316
    [No Abstract]   [Full Text] [Related]  

  • 5. Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression.
    Ferrer I; López-González I; Carmona M; Arregui L; Dalfó E; Torrejón-Escribano B; Diehl R; Kovacs GG
    J Neuropathol Exp Neurol; 2014 Jan; 73(1):81-97. PubMed ID: 24335532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies.
    Fuster-Matanzo A; Hernández F; Ávila J
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prion-like Spreading in Tauopathies.
    Ayers JI; Giasson BI; Borchelt DR
    Biol Psychiatry; 2018 Feb; 83(4):337-346. PubMed ID: 28506438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycation alter the process of Tau phosphorylation to change Tau isoforms aggregation property.
    Liu K; Liu Y; Li L; Qin P; Iqbal J; Deng Y; Qing H
    Biochim Biophys Acta; 2016 Feb; 1862(2):192-201. PubMed ID: 26655600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Disorders with Tau Pathology: A Review of the Literature and Report of Two Patients with Tauopathy and Positive Family Histories.
    Tacik P; Sanchez-Contreras M; Rademakers R; Dickson DW; Wszolek ZK
    Neurodegener Dis; 2016; 16(1-2):12-21. PubMed ID: 26550830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins.
    Dickey CA; Kamal A; Lundgren K; Klosak N; Bailey RM; Dunmore J; Ash P; Shoraka S; Zlatkovic J; Eckman CB; Patterson C; Dickson DW; Nahman NS; Hutton M; Burrows F; Petrucelli L
    J Clin Invest; 2007 Mar; 117(3):648-58. PubMed ID: 17304350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of hippocampal tau pathology differentiate neurodegenerative dementias.
    Milenkovic I; Petrov T; Kovacs GG
    Dement Geriatr Cogn Disord; 2014; 38(5-6):375-88. PubMed ID: 25195847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
    Lewis J; Dickson DW
    Acta Neuropathol; 2016 Jan; 131(1):27-48. PubMed ID: 26576562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.
    Javidnia M; Hebron ML; Xin Y; Kinney NG; Moussa CE
    J Alzheimers Dis; 2017; 60(2):461-481. PubMed ID: 28869476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frontotemporal dementia with tau pathology.
    Gasparini L; Terni B; Spillantini MG
    Neurodegener Dis; 2007; 4(2-3):236-53. PubMed ID: 17596718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two days of tau: a meeting focused on its biology and pathology.
    Skoulakis EM; Mudher A
    Biochem Soc Trans; 2010 Aug; 38(4):953-4. PubMed ID: 20658983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies.
    Julien C; Bretteville A; Planel E
    Methods Mol Biol; 2012; 849():473-91. PubMed ID: 22528110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies?
    Alavi Naini SM; Soussi-Yanicostas N
    Oxid Med Cell Longev; 2015; 2015():151979. PubMed ID: 26576216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain.
    Narasimhan S; Guo JL; Changolkar L; Stieber A; McBride JD; Silva LV; He Z; Zhang B; Gathagan RJ; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Nov; 37(47):11406-11423. PubMed ID: 29054878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
    Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.